Bal Pharma Limited

BSE: 524824 NSE: BALPHARMA
Bal Pharma Limited - pharma in Bangalore South, Karnataka, India. FY 2026 financials & compliance.
CIN L85110KA1987PLC008368 Incorporated 19 May 1987 ROC Bangalore HQ Bangalore South, Karnataka, India
Active Listed - NSE: BALPHARMA · BSE: 524824 Public Limited Company pharma
Data last updated
Market Cap
₹167 Cr
BALPHARMA · NSE
Share Price
₹107.71
+2.56% today
Revenue
₹312 Cr
FY 2025-26 · +2.4% YoY
EBITDA
₹31.90 Cr
Margin 10.2%
Net Profit
₹6.28 Cr
FY 2025-26 · -13.0% YoY
P/E (TTM)
23.9x
P/B 2.1x

About Bal Pharma Limited

Data last updated: 26 September 2026

Bal Pharma Limited is a public limited company based in Bangalore South, Karnataka, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 19 May 1987, the company has been in operation for over 39 years.

Registered with ROC Bangalore under CIN L85110KA1987PLC008368. Listed on BSE: 524824 and NSE: BALPHARMA.

Capital: an authorised share capital of ₹24.5 Cr and a paid-up capital of ₹15.92 Cr. It is led by directors including Jatish Sheth and Nicola Neeladri.

Last AGM: 25 September 2025. Financial statements filed for year ended 31 March 2025. Office: Bangalore South, Karnataka.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹311.66 Cr, a growth of 2.83% compared to the previous year.

The company has a workforce of approximately 715 employees as per the latest available data. Its group structure includes 4 subsidiaries.

The company is associated with 1 brand - Bal Pharma. As per MCA filings, the company has open charges of ₹234.22 Cr and satisfied charges of ₹198.12 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website balpharma.com.

Company Details of Bal Pharma Limited
CIN L85110KA1987PLC008368
Registration Number 008368
Incorporation Date 19 May 1987
ROC Bangalore
Listing Status Listed (BSE: 524824, NSE: BALPHARMA)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Shailesh Siroya Managing Director Virupakshaya Himesh Whole-Time Director Jatish Sheth Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    balpharma.com
  • Social Media
  • Registered Address
    21 – 22 Bommasandra, Industrial Area, Bangalore South, Karnataka, India – 560099
  • Industry
    Pharma, API Manufacturers
Company report
Bal Pharma Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Bal Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Bal Pharma Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Bal Pharma Limited

Bal Pharma Limited operates one associated brand: Bal Pharma. These brands represent Bal Pharma Limited's diversified market presence and brand portfolio.

Brand Description Website
Bal Pharma
Manufacturer of pharmaceutical APIs, formulations, and Ayurvedic products balpharma.com

Business Activity of Bal Pharma Limited

Bal Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Bal Pharma Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Bal Pharma Limited

Bal Pharma Limited is audited by S S J N B & CO for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
S S J N B & CO Locked Locked Locked
Premium access

Complete auditor history for Bal Pharma Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Bal Pharma Limited

Bal Pharma Limited is currently managed by 6 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Jatish Sheth
Also directs: Meganza Pharma Llp, Srushti Pharmaceuticals Private Limited
Director 28 Dec 2020 5 Years 8 Months Current
Nicola Neeladri
Also directs: Umiya Buildcon Limited, Isg Novasoft Technologies Limited, Bluetech Design Private Limited
Director 23 May 2020 6 Years 4 Months Current
Shailesh Siroya
Also directs: Balance Clinics Llp, Lifezen Healthcare Private Limited, Kaunshya Investments Private Limited and 2 more
Managing Director 01 Aug 2004 22 Years 1 Months Current
Virupakshaya Himesh Whole-Time Director 28 Sep 2019 6 Years 11 Months Current
Bheekamchand Mukesh Additional Director 13 Nov 2025 0 Years 10 Months Current
Ravindrakumar Kothari
Also directs: Balance Clinics Llp, Lifezen Healthcare Private Limited, Aurum Research & Analytical Solutions Private Limited and 1 more
Director 05 May 2025 1 Years 4 Months Current
View all directors

Financials of Bal Pharma Limited FY 2025-26 filings available

Bal Pharma Limited reported revenue of ₹311.66 Cr (up 2.83% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹312 Cr
+2.8% YoY
EBITDA
₹31.90 Cr
+7.2% YoY
Profit After Tax
₹6.28 Cr
-13.0% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue312303339304281251171
Revenue growth+2.4%-11.4%+10.5%+8.4%+13.9%+36.0%-19.9%
EBITDA31.9029.7630.9225.2623.9724.645.02
EBITDA margin+10.2%+9.8%+9.1%+8.3%+8.5%+9.8%+2.9%
Profit before tax5.935.149.034.769.174.10(13.54)
Net profit6.287.227.322.564.974.72(12.28)
Net profit margin+2.0%+2.4%+2.2%+0.8%+1.8%+1.9%-7.2%
EPS (₹)3.954.534.681.643.793.20(8.62)
Balance sheet
Total assets-235218201171171171
Net worth-77.4272.0063.7958.6353.5852.42
Total debt-150140131104110118
Cash & bank-8.0513.297.615.393.853.13
Net working capital-13212811995.5597.7193.18
Cash flow
Cash from operations-20.3222.81(1.54)27.7122.3423.24
Cash from investing-(14.92)(18.89)(22.18)(9.48)(5.54)(4.85)
Cash from financing-(7.84)(1.21)24.09(18.13)(16.63)(19.97)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue88.6284.0887.6974.0265.8781.8873.1573.69
Revenue growth (YoY)+34.5%+2.7%+19.9%+0.5%-11.4%-13.5%-10.4%-20.4%
Other income0.44(0.24)0.331.120.721.080.51(0.20)
EBITDA7.9510.579.555.736.067.647.757.69
EBITDA margin+9.0%+12.6%+10.9%+7.7%+9.2%+9.3%+10.6%+10.4%
Depreciation2.783.063.232.272.522.182.692.48
Interest4.474.064.853.864.053.955.013.65
Profit before tax1.143.211.800.720.212.590.561.36
Tax0.00(0.39)0.000.000.00(2.82)0.040.32
Net profit1.143.601.800.720.215.410.521.04
EPS (₹)0.712.261.120.450.133.400.330.65
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue311302339303280249171
Revenue growth+2.3%-11.3%+10.9%+7.8%+15.3%+36.1%-19.2%
EBITDA32.2330.2831.7226.4323.7026.617.02
EBITDA margin+10.4%+10.0%+9.4%+8.7%+8.5%+10.7%+4.1%
Profit before tax6.365.749.338.5512.059.79(9.07)
Net profit6.757.817.686.107.799.05(8.89)
Net profit margin+2.2%+2.6%+2.3%+2.0%+2.8%+3.6%-5.2%
EPS (₹)4.514.904.893.905.796.14(6.28)
Balance sheet
Total assets-250233227194191172
Net worth-98.8292.8396.0387.3279.3265.94
Total debt-14513412598.0110499.43
Cash & bank-7.9413.157.355.093.722.95
Net working capital-145140152127127105
Cash flow
Cash from operations-20.3128.545.3831.4810.2321.71
Cash from investing-(14.90)(18.84)(22.08)(13.43)(6.66)(3.30)
Cash from financing-(7.83)(6.94)17.12(18.13)(3.36)(19.94)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue88.4383.9287.4973.7565.6481.7872.8974.70
Revenue growth (YoY)+34.7%+2.6%+20.0%-1.3%-10.2%-13.5%-10.6%-19.1%
Other income0.46(0.22)0.351.130.740.990.510.35
Total expenses80.4873.2977.8267.9859.4873.9564.9567.22
EBITDA7.9510.639.675.776.167.837.947.48
EBITDA margin+9.0%+12.7%+11.1%+7.8%+9.4%+9.6%+10.9%+10.0%
Depreciation2.783.043.232.272.522.072.682.12
Interest4.474.054.853.864.053.945.024.18
Profit before tax1.163.321.940.770.332.810.751.53
Tax0.00(0.39)0.000.000.00(2.79)0.040.32

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue88.6284.0887.6974.0265.8781.8873.1573.69
Revenue growth (YoY)+34.5%+2.7%+19.9%+0.5%-11.4%-13.5%-10.4%-20.4%
Other income0.44(0.24)0.331.120.721.080.51(0.20)
EBITDA7.9510.579.555.736.067.647.757.69
EBITDA margin+9.0%+12.6%+10.9%+7.7%+9.2%+9.3%+10.6%+10.4%
Depreciation2.783.063.232.272.522.182.692.48
Interest4.474.064.853.864.053.955.013.65
Profit before tax1.143.211.800.720.212.590.561.36
Tax0.00(0.39)0.000.000.00(2.82)0.040.32
Net profit1.143.601.800.720.215.410.521.04
EPS (₹)0.712.261.120.450.133.400.330.65
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue312303339304281251171
Revenue growth+2.4%-11.4%+10.5%+8.4%+13.9%+36.0%-19.9%
Other income1.932.202.850.945.151.141.85
Total expenses280273308279257226166
Employee cost0.0062.4060.4855.3047.2541.8850.44
EBITDA31.9029.7630.9225.2623.9724.645.02
EBITDA margin+10.2%+9.8%+9.1%+8.3%+8.5%+9.8%+2.9%
Depreciation11.089.7710.079.139.049.527.68
Interest16.8217.0514.6712.3110.9112.1612.73
Profit before tax5.935.149.034.769.174.10(13.54)
Tax(0.39)(2.10)1.612.133.48(0.61)(0.64)
Net profit6.287.227.322.564.974.72(12.28)
Net profit margin+2.0%+2.4%+2.2%+0.8%+1.8%+1.9%-7.2%
EPS (₹)3.954.534.681.643.793.20(8.62)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-15.9215.8015.6914.8214.8214.17
Reserves & surplus-61.5056.2048.1042.8737.8238.25
Shareholders' funds (net worth)-77.4272.0063.7958.6353.5852.42
Minority interest-(0.01)(0.03)(0.09)(0.13)(0.23)(7.10)
Secured loans-14513412597.7110498.63
Unsecured loans-5.775.775.775.935.9819.82
Total debt-150140131104110118
Total liabilities-235218201171171171
Assets
Gross block-15714012711110597.70
Net block-86.8179.5276.4667.3968.5870.70
Capital work in progress-2.790.470.001.610.003.32
Investments-2.476.760.000.000.000.00
Inventories-10387.8198.0174.4060.3967.71
Sundry debtors-92.4499.6293.9875.3167.2049.60
Cash & bank balances-8.0513.297.615.393.853.13
Loans & advances-28.8926.6828.5629.4732.7236.92
Total current assets-232227228185164157
Total current liabilities-10199.8110989.0266.4564.18
Net working capital-13212811995.5597.7193.18
Total assets-235218201171171171
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-4.201.491.111.020.862.44
Net cash from operating activities-20.3222.81(1.54)27.7122.3423.24
Net cash from investing activities-(14.92)(18.89)(22.18)(9.48)(5.54)(4.85)
Net cash from financing activities-(7.84)(1.21)24.09(18.13)(16.63)(19.97)
Net change in cash-(2.44)2.710.370.090.16(1.58)
Closing cash-8.0513.297.615.393.853.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.8%-10.7%+11.5%+8.2%+12.3%+46.4%-24.0%
EBITDA growth+7.2%-3.8%+22.4%+5.4%-2.7%+390.8%-71.6%
PBT growth+15.4%-43.1%+89.7%-48.1%+123.7%+9998.0%-7026.3%
Net income growth-13.0%-1.4%+185.9%-48.5%+5.3%+9998.0%-
Revenue CAGR (3Y)+0.8%+2.5%+10.6%+21.2%+7.7%+5.8%-9.3%
EBITDA CAGR (3Y)+8.1%+7.5%+7.9%+71.4%+10.7%+12.4%-30.3%
Profitability & leverage
Net income margin+2.0%+2.4%+2.2%+0.9%+2.0%+1.9%-7.5%
Return on capital employed-+9.8%+11.3%+9.2%+11.0%+9.3%-0.4%
Return on net worth-+9.7%+11.0%+4.3%+9.0%+8.9%-21.7%
Debt / equity-1.941.991.921.902.162.03
Long-term debt / equity-0.450.490.470.340.410.44
Interest cover80.7985.2970.3676.3273.0780.42-478.57
Efficiency & per share
Fixed asset turnover-2.042.542.552.602.471.83
Inventory turnover-3.183.653.534.173.912.49
Debtors turnover-3.163.503.593.954.292.99
EPS (₹)3.954.534.681.643.793.20(8.62)
Dividend per share (₹)1.201.201.201.001.001.000.00
Book value per share (₹)0.0048.6345.5640.6638.9235.5236.99
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue88.4383.9287.4973.7565.6481.7872.8974.70
Revenue growth (YoY)+34.7%+2.6%+20.0%-1.3%-10.2%-13.5%-10.6%-19.1%
Other income0.46(0.22)0.351.130.740.990.510.35
Total expenses80.4873.2977.8267.9859.4873.9564.9567.22
EBITDA7.9510.639.675.776.167.837.947.48
EBITDA margin+9.0%+12.7%+11.1%+7.8%+9.4%+9.6%+10.9%+10.0%
Depreciation2.783.043.232.272.522.072.682.12
Interest4.474.054.853.864.053.945.024.18
Profit before tax1.163.321.940.770.332.810.751.53
Tax0.00(0.39)0.000.000.00(2.79)0.040.32
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue311302339303280249171
Revenue growth+2.3%-11.3%+10.9%+7.8%+15.3%+36.1%-19.2%
Other income2.002.152.302.196.492.693.63
Total expenses279272307277257223164
Employee cost0.0061.8359.5751.5644.4639.6248.78
EBITDA32.2330.2831.7226.4323.7026.617.02
EBITDA margin+10.4%+10.0%+9.4%+8.7%+8.5%+10.7%+4.1%
Depreciation11.069.6510.057.487.247.267.03
Interest16.8117.0414.6412.5910.9012.2512.69
Profit before tax6.365.749.338.5512.059.79(9.07)
Tax(0.39)(2.07)1.602.423.480.70(0.18)
Net profit6.757.817.686.107.799.05(8.89)
Net profit margin+2.2%+2.6%+2.3%+2.0%+2.8%+3.6%-5.2%
EPS (₹)4.514.904.893.905.796.14(6.28)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-15.9215.8015.6914.8214.8214.17
Reserves & surplus-82.9077.0380.3471.5663.5651.77
Shareholders' funds (net worth)-98.8292.8396.0387.3279.3265.94
Secured loans-14513412597.8410498.63
Unsecured loans-0.000.000.000.170.210.80
Total debt-14513412598.0110499.43
Total liabilities-250233227194191172
Assets
Gross block-15714010792.1286.1382.36
Net block-86.7779.3863.0752.9052.6556.13
Capital work in progress-2.790.470.001.160.000.11
Investments-4.638.928.408.408.407.42
Inventories-10387.5397.6973.9760.1267.55
Sundry debtors-94.8510294.8477.9169.4451.66
Cash & bank balances-7.9413.157.355.093.722.95
Loans & advances-39.6237.2570.0763.2959.9246.55
Total current assets-245240270220193169
Total current liabilities-10099.6511793.5966.5663.66
Net working capital-145140152127127105
Total assets-250233227194191172
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-4.061.300.810.890.682.20
Net cash from operating activities-20.3128.545.3831.4810.2321.71
Net cash from investing activities-(14.90)(18.84)(22.08)(13.43)(6.66)(3.30)
Net cash from financing activities-(7.83)(6.94)17.12(18.13)(3.36)(19.94)
Net change in cash-(2.42)2.760.42(0.08)0.21(1.52)
Closing cash-7.9413.157.355.093.722.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.7%-10.7%+11.7%+8.1%+12.5%+46.1%-23.5%
EBITDA growth+6.4%-4.5%+20.0%+11.5%-10.9%+279.1%-65.7%
PBT growth+10.8%-38.5%+9.1%-29.1%+23.1%+9998.0%-
Net income growth-13.6%+1.7%+25.9%-21.7%-13.9%+9998.0%-
Revenue CAGR (3Y)+0.8%+2.6%+10.7%+21.1%+7.9%+5.9%-8.9%
EBITDA CAGR (3Y)+6.8%+8.5%+6.0%+55.6%+5.0%+5.1%-29.6%
Profitability & leverage
Net income margin+2.2%+2.6%+2.3%+2.0%+3.1%+3.7%-5.2%
Return on capital employed-+9.4%+10.4%+10.1%+11.3%+12.2%+2.0%
Return on net worth-+8.1%+8.2%+6.7%+9.4%+12.5%-12.5%
Debt / equity-1.451.371.221.211.401.43
Long-term debt / equity-0.350.350.310.230.300.36
Interest cover79.4082.6067.5666.4466.2263.31-1,26,900.00
Efficiency & per share
Fixed asset turnover-2.042.743.043.152.962.15
Inventory turnover-3.183.663.534.183.912.49
Debtors turnover-3.083.443.513.814.122.91
EPS (₹)4.514.904.893.905.796.14(6.28)
Dividend per share (₹)1.201.201.201.001.001.000.00
Book value per share (₹)0.0062.0758.7461.2158.2852.8846.53
Want more history and ratios?
You're viewing the latest exchange-filed financials for Bal Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Bal Pharma Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 50.90%, foreign institutional investors hold 0.20%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 49.00% of Bal Pharma Limited.

Promoters: 50.90%FII (Foreign Institutional): 0.20%Retail & Others: 49.00%
Jun 2026
QUARTER
50.90% Promoters
0.20% FII (Foreign Institutional)
49.00% Retail & Others
Promoter holding - history
Now 50.90% · Jun 2026High 50.90% · Sep 2025Low 50.90% · Sep 2025
49%49.8%50.5%51.3%52%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 50.90%Dec 2025: 50.90%Mar 2026: 50.90%Jun 2026: 50.90%50.90%50.90%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters50.90%50.90%50.90%50.90%
Public49.10%49.10%49.10%49.10%

Group Structure of Bal Pharma Limited

Bal Pharma Limited has 4 subsidiary companies. This group structure data is as of FY 2024. The corporate group structure reflects Bal Pharma Limited's business expansion strategy and organizational complexity.

4
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Lifezen Healthcare Private Limited U24230KA2014PTC077114 -
Golden Drugs Private Limited U24232KA2012PTC157474 -
Aurum Research & Analytical Solutions Private Limited U72100KA2023PTC177577 -
Bal Research Foundation U73100KA2014NPL076995 -

Showing major subsidiaries. Total: 4.

Charges & Borrowings of Bal Pharma Limited

Open charges
₹234.22 Cr
Satisfied charges
₹198.12 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹106.58 Cr
Others₹64.83 Cr
Canara Bank₹58.15 Cr
Sidbi₹4.29 Cr
Axis Bank Limited₹0.36 Cr
Latest charge details
DateLenderAmountStatus
20 Nov 2025 Others ₹4.4 Cr Open
13 Nov 2025 Hdfc Bank Limited ₹5 Cr Open
23 Oct 2025 Hdfc Bank Limited ₹24.9 Lakh Open
28 Aug 2025 Others ₹22 Cr Open
22 Aug 2025 Others ₹3 Cr Open

Total charge records: 41 View all charges

Employees and EPFO Compliance at Bal Pharma Limited

Bal Pharma Limited has a workforce of 715 employees as of Mar 31, 2025.

Employee count
715
Active EPFO establishments
2
Employee growth
-12.7%
Premium access

Employee and EPFO history for Bal Pharma Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Bal Pharma Limited

Premium access

GST registrations and filing compliance for Bal Pharma Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Bal Pharma Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Bal Pharma Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Bal Pharma Limited

Premium access

MSME payment history for Bal Pharma Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Bal Pharma Limited

Premium access

Corporate group structure for Bal Pharma Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Bal Pharma Limited

Premium access

MCA filings and documents for Bal Pharma Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Bal Pharma Limited

Directors
26 Jun 2026
Makkigadde Lakshminarayana Shreepada was appointed as a Company Secretary on 26 Jun 2026 & has been associated with this company since 3 months 3 days.
Charges
17 Jan 2026
A charge with Hdfc Bank Limited of Rs. 5.00 Cr registered on 13 Nov 2025 with Charge ID 101183756 was modified on 17 Jan 2026.
Charges
12 Dec 2025
A charge with Canara Bank of Rs. 58.05 Cr registered on 10 May 2019 with Charge ID 100264149 was modified on 12 Dec 2025.
Charges
27 Nov 2025
A charge with Others of Rs. 22.00 Cr registered on 28 Aug 2025 with Charge ID 101169142 was modified on 27 Nov 2025.
Charges
20 Nov 2025
A charge with Others amounted to Rs. 4.40 Cr with Charge ID 101186985 was registered on 20 Nov 2025.
Charges
13 Nov 2025
A charge with Hdfc Bank Limited amounted to Rs. 5.00 Cr with Charge ID 101183756 was registered on 13 Nov 2025.

Recent News on Bal Pharma Limited

Bal Pharma, Australian co venture
06 Mar 2018 · Business Line

Frequently Asked Questions about Bal Pharma Limited

Bal Pharma Limited is an active public limited company in the pharma sector based in Bangalore South, Karnataka, India. It was incorporated on 19 May 1987 (39+ years old) and is registered under CIN L85110KA1987PLC008368. Listed on BSE: 524824 and NSE: BALPHARMA. The company has 715 employees.

Bal Pharma Limited reported revenue of ₹311.66 Cr for FY 2025-26 (up 2.83% YoY) based on consolidated financials.

The current directors of Bal Pharma Limited are:

The primary industry of Bal Pharma Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Bal Pharma Limited is listed on both BSE (code: 524824) and NSE (symbol: BALPHARMA).

Bal Pharma Limited can be reached at the registered office: 21 – 22 Bommasandra, Industrial Area, Bangalore South, Karnataka, India – 560099, or through the website balpharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available